Transitioning from Metoprolol to Telmisartan in Hypertension

Introduction to Transitioning

The American Heart Association recommends reducing metoprolol dose by approximately 25-50% every 1-2 weeks to minimize withdrawal risks, with a strength of evidence level of high 1
The European Heart Journal suggests that beta-blockers are not first-line agents for uncomplicated hypertension and should be reserved for compelling indications such as coronary artery disease, heart failure, or post-myocardial infarction, with a strength of evidence level of moderate 2

The European Society of Cardiology recommends tapering metoprolol over 1-2 weeks to avoid severe exacerbation of angina, myocardial infarction, ventricular arrhythmias, and rebound hypertension, with a documented 50% mortality in one study, and a strength of evidence level of high 1
For a patient on metoprolol 25mg daily, reduce to 12.5mg daily for 1-2 weeks, monitoring blood pressure and heart rate closely, then discontinue, with a strength of evidence level of high 1

The American College of Cardiology recommends starting telmisartan 40mg once daily when beginning the metoprolol taper, with a strength of evidence level of moderate 3
Target blood pressure should be <140/90 mmHg minimum, ideally <130/80 mmHg for most patients, with a strength of evidence level of high 3, 4

Check blood pressure and heart rate every 3-4 days initially, and watch for signs of worsening hypertension or symptomatic bradycardia, with a strength of evidence level of moderate 1, 3
Reassess blood pressure within 2-4 weeks after completing metoprolol discontinuation, with a strength of evidence level of high 3, 4

The European Society of Cardiology recommends maintaining metoprolol at current dose or uptitrating to target dose of 200mg daily for patients with heart failure with reduced ejection fraction, with a strength of evidence level of high 1
For patients with coronary artery disease or prior MI, do not discontinue metoprolol, and instead add telmisartan 40mg to metoprolol 25mg for combination therapy, with a strength of evidence level of moderate 3

Never abruptly stop metoprolol without tapering, as this can precipitate life-threatening cardiovascular events, with a strength of evidence level of high 1
Avoid combining telmisartan with an ACE inhibitor, as dual RAS blockade increases adverse events without additional cardiovascular benefit, with a strength of evidence level of high 3, 4